The Contribution of Lp-PLA2 Level to the Presence of Coronary Plaques in Patients With Non Alcoholic Fatty Liver Disease (0030-10)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01139632|
Recruitment Status : Unknown
Verified June 2010 by Ziv Hospital.
Recruitment status was: Active, not recruiting
First Posted : June 8, 2010
Last Update Posted : April 6, 2011
|Condition or disease|
|Nonalcoholic Fatty Liver Disease Coronary Artery Disease|
Background: The most common cause of death in patients with NAFLD(Nonalcoholic Fatty Liver Disease) is CAD(Coronary Artery Disease). NAFLD patients have 65% more mortality than general population. The aim of our study is to diagnose early coronary artery disease in NAFLD patient by measuring of PLA2.
Methods: 60 patients with chest pain and low to intermediate risk for coronary events will undergo Cardiac CT and blood test measurement of enzyme PLA2, markers of inflammation: CRP, MDA(Malondialdehide), Paraoxonase, FFA(Free Fatty Acids), TG(Triglycerids) will performed.
CAD is defined as a stenosis of more than 50% in at least one major coronary artery, unstable plaque defined as low attenuated plaque <30HU and fatty liver defined as difference in liver and spleen attenuation value -10HU by using CT.
Expected results : we expect that PLA2 will higher in patients with patients with combination of CAD, unstable plaque and NAFLD.
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||The Contribution of Lp-PLA2 Level to the Presence of Coronary Plaques in Patients With Non Alcoholic Fatty Liver Disease|
|Study Start Date :||July 2010|
|Estimated Primary Completion Date :||January 2011|
|Estimated Study Completion Date :||March 2011|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01139632
|Ziv medical center liver unit|
|Safed, Israel, Israel, 13100|
|Principal Investigator:||Nimer Assy, MD||ZIV MEDICAL CENTER, SAFED ISRAEL|